Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook

References

• Henderson DA, Borio LL, Grabenstein JD. Smallpox and vaccinia. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, Amsterdam, The Netherlands 773–803 (2008).
   Google Scholar
• Weniger BG, Papania MJ. Alternative vaccine delivery methods. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, Amsterdam, The Netherlands, 1357–1392 (2008).
   Google Scholar
• Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J. Control Release66, 199–214 (2000).
   PubMed Web of Science ®Google Scholar
• Larregina AT, Falo LD. Changing paradigms in cutaneous immunology: adapting with dendritic cells. J. Invest. Dermatol.124, 1–12 (2005).
   PubMed Web of Science ®Google Scholar
• Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nature Rev. Immunol.5, 617–628 (2005).
   PubMed Web of Science ®Google Scholar
• Reddy ST, van der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol.25, 1159–1164 (2007).
   PubMed Web of Science ®Google Scholar
• Cardell K, Fryden A,Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Scand. J. Infect. Dis.31, 197–200 (1999).
   PubMedGoogle Scholar
• Carlsson T, Struve J, Sonnerborg A, Weiland O. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand. J. Infect. Dis.31, 93–95 (1999).
   PubMedGoogle Scholar
• Egemen A, Aksit S, Kurugol Z, Erensoy S, Bilgic A, Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine16, 1511–1515 (1998).
   PubMed Web of Science ®Google Scholar
• Ghabouli MJ, Sabouri AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur. J. Epidemiol.19, 871–875
   PubMedGoogle Scholar
• Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect. Control Hosp. Epidemiol.21, 264–269 (2000).
   PubMed Web of Science ®Google Scholar
• Jaiswal SP, Asolkar MV, Vijayvargiya R, Chitnis DS. Immunogenicity of low-dose hepatitis-B vaccine by the intradermal route and persistence of anti-HBs after 3 years. Indian J. Med. Res.102, 129–133 (1995).
   PubMedGoogle Scholar
• Kurugol Z, Erensoy S, Aksit S, Egemen A, Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study. Vaccine19, 3936–3939 (2001).
   PubMedGoogle Scholar
• Kyi KP, Oo KM, Htun MM et al. Clinical trial of the intradermal administration of hepatitis B vaccine produced at the Department of Medical Research, Myanmar. Vaccine20, 1649–1652 (2002).
   PubMedGoogle Scholar
• Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis-B vaccine in health-care workers who failed to respond to intramuscular vaccination. Infect. Control Hosp. Epidemiol.16, 88–91 (1995).
   PubMedGoogle Scholar
• Playford EG, Hogan PG, Bansal AS et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect. Control Hosp. Epidemiol.23, 87–90 (2002).
   PubMedGoogle Scholar
• Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology31, 521–527 (2000).
   PubMed Web of Science ®Google Scholar
• Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Response to a booster dose 18 months after a low anti-HBs response (10–99 IU/l) to 3 doses of intradermally or intramuscularly administered recombinant hepatitis-B vaccine. Infection23, 42–45 (1995).
   PubMedGoogle Scholar
• Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. Vaccine15, 1618–1623 (1997).
   PubMedGoogle Scholar
• Zhuang GH, Yan H, Wang XL et al. Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. Vaccine24, 2186–2192 (2006).
   PubMedGoogle Scholar
• Angelico M, Di Paolo D, Trinito MO et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology35, 176–181 (2002).
   PubMed Web of Science ®Google Scholar
• Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am. J. Kidney Dis.36, 976–982 (2000).
   PubMed Web of Science ®Google Scholar
• Chau KF, Cheng YL, Tsang DNC et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am. J. Kidney Dis.43, 910–917 (2004).
   PubMed Web of Science ®Google Scholar
• Choy BY, Peiris JSM, Chan TM, Lo SKF, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am. J. Transplant.2, 965–969 (2002).
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost–effectiveness evaluation. Nephrol. Dialysis Transplant.12, 1204–1211 (1997).
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment. Pharmacol. Ther.24, 497–506 (2006).
   PubMed Web of Science ®Google Scholar
• Karahocagil MK, Buzgan T, Irmak H, Karsen H, Akdeniz H, Akman N. Comparison of intramuscular and intradermal applications of hepatitis B vaccine in hemodialysis patients. Renal Failure28, 561–565 (2006).
   PubMedGoogle Scholar
• Mettang T, Schenk U, Thomas S et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure – a preliminary study. Nephron72, 192–196 (1996).
   PubMedGoogle Scholar
• Morais EO, Resende MR, Oliveira AM et al. Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up. Aliment. Pharmacol. Ther.25, 849–855 (2007).
   PubMed Web of Science ®Google Scholar
• Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am. J. Kidney Dis.32, 1041–1045 (1998).
   PubMed Web of Science ®Google Scholar
• Vlassopoulos D, Arvanitis D, Lilis D, Hatjiyannakos D, Louizou K, Hadjiconstantinou V. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Renal Failure19, 455–460 (1997).
   PubMed Web of Science ®Google Scholar
• Vlassopoulos DA, Arvanitis DK, Lilis DS, Louizou KI, Hadjiconstantinou VE. Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. Int. J. Art. Organs22, 739–743 (1999).
   PubMed Web of Science ®Google Scholar
• Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis-B vaccine in hemodialysis-patients previously nonresponsive to intramuscular hepatitis-B vaccine. J. Amer. Soc. Nephrol.5, 1930–1934 (1995).
   PubMed Web of Science ®Google Scholar
• Nagafuchi S, Kashiwagi S, Imayama S, Hayashi J, Niho Y. Intradermal administration of viral vaccines. Rev. Med. Virol.8, 97–111 (1998).
   PubMedGoogle Scholar
• Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine20, 2562–2578 (2002).
   PubMed Web of Science ®Google Scholar
• Vajdy M, Baudner B, Del Giudice G, O’Hagan D. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin. Immunol.123, 166–175 (2007).
   PubMed Web of Science ®Google Scholar
• Brooks JH, Criep LH, Ruben FL. Intradermal administration of bivalent and monovalent influenza vaccines. Ann. Allergy39, 110–112 (1977).
   PubMedGoogle Scholar
• Brown H, Kasel JA, Freeman DM, Moise LD, Grose NP, Couch RB. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J. Infect. Dis.36 Suppl. S466–S471 (1977).
   Google Scholar
• Halperin W, Weiss WI, Altman R et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am. J. Pub. Health69, 1247–1250 (1979).
   PubMed Web of Science ®Google Scholar
• Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J. Infect. Dis.140, 234–238 (1979).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med.351, 2286–2294 (2004).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med.351, 2295–2301 (2004).
   PubMed Web of Science ®Google Scholar
• Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine25, 659–663 (2006).
   PubMedGoogle Scholar
• Chiu SS, Peiris JSM, Chan KH, Wong WHS, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics119, 1076–1082 (2007).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine25, 6755–6763 (2007).
   PubMed Web of Science ®Google Scholar
• Booy R, Weber F, Saville M. Immunogenicity of a novel influenza vaccine delivered by intradermal microinjection in over 60-year-olds. Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17–23 June 2007.
   Google Scholar
• Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis.198(5), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• Alfonso M, Diaz A, Hernandez AM et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol.168, 2523–2529 (2002).
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol.22, 403–415 (2004).
   PubMed Web of Science ®Google Scholar
• Dessureault S, Noyes D, Lee D et al. A Phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol.14, 869–884 (2007).
   PubMed Web of Science ®Google Scholar
• Hunger RE, Brand CU, Streit M et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol.10, 161–167 (2001).
   PubMed Web of Science ®Google Scholar
• Kruit WHJ, van Ojik HH, Brichard VG et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer117, 596–604 (2005).
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther.13, 905–918 (2006).
   PubMed Web of Science ®Google Scholar
• O’Rourke MGE, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother.52, 387–395 (2003).
   PubMed Web of Science ®Google Scholar
• Salcedo M, Bercovici N, Taylor R et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother.55, 819–829 (2006).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Kampgen E, Wagner E et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2 transfected cancer cells: outcome of a Phase I study. Hum. Gene Ther.10, 983–993 (1999).
   PubMed Web of Science ®Google Scholar
• Trakatelli M, Toungouz M, Blocklet D et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T-cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol. Immunother.55, 469–474 (2006).
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK et al. Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother.55, 1553–1564 (2006).
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res.11, 3017–3024 (2005).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Sterman D, Jablons D et al. Granulocyte–macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl Cancer Inst.96, 326–331 (2004).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Dissette VB et al. A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides. Clin. Cancer Res.12, 2817–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Meng WS et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res.9, 5902–5908 (2003).
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating Phase I/II study. Br. J. Cancer95, 1474–1482 (2006).
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Buanes T, Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte–macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer92, 441–450 (2001).
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neurooncology6, 236–246 (2004).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115, 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet363, 594–599 (2004).
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase 1 study. J. Immunother.25, 500–508 (2002).
   PubMed Web of Science ®Google Scholar
• Pandha HS, John RJ, Hutchinson J et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a Phase I/II study. Br. J. Urol. Int.94, 412–418 (2004).
   Google Scholar
• Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer. Cancer Res.57, 1537–1546 (1997).
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res.63, 2127–2133 (2003).
   PubMed Web of Science ®Google Scholar
• Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res.5, 1289–1297 (1999).
   PubMed Web of Science ®Google Scholar
• Guthmann MD, Castro MA, Cinat G et al. Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J. Immunother.29, 215–223 (2006).
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika A, Osada T et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J. Transl. Med.5, 42 (2007).
   PubMed Web of Science ®Google Scholar
• Murray JL, Gillogly ME, Przepiorka D et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+patients with metastatic breast and ovarian cancer. Clin. Cancer Res.8, 3407–3418 (2002).
   PubMed Web of Science ®Google Scholar
• Nicholson S, Bomphray CC, Thomas H et al. A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother.53, 809–816 (2004).
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol.166, 4254–4259 (2001).
   PubMed Web of Science ®Google Scholar
• Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest.109, 409–417 (2002).
   PubMed Web of Science ®Google Scholar
• Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol. Immunother.55, 1432–1442 (2006).
   PubMed Web of Science ®Google Scholar
• Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res.11, 4469–4478 (2005).
   PubMed Web of Science ®Google Scholar
• Mincheff M, Tchakarov S, Zoubak S et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur. Urol.38, 208–217 (2000).
   PubMed Web of Science ®Google Scholar
• Perambakam S, Hallmeyer S, Reddy S et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol. Immunother.55, 1033–1042 (2006).
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+T cell responses in patients with metastatic prostate cancer. J. Immunol.174, 3798–3807 (2005).
   PubMed Web of Science ®Google Scholar
• Oki Y, McLaughlin P, Fayad LE et al. Experience with heat shock protein–peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer109, 77–83 (2007).
   PubMed Web of Science ®Google Scholar
• Bertinetti C, Zirlik K, Heining-Mikesch K et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res.66, 4496–4502 (2006).
   PubMed Web of Science ®Google Scholar
• Mosolits S, Markovic K, Frodin JE et al. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin. Cancer Res.10, 5391–5402 (2004).
   PubMed Web of Science ®Google Scholar
• Lomas M, Liauw W, Packham D et al. Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Ann. Oncol.15, 324–329 (2004).
   PubMedGoogle Scholar
• Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol.171, 6275–6282 (2003).
   PubMed Web of Science ®Google Scholar
• Morse MA, Deng YP, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res.5, 1331–1338 (1999).
   PubMed Web of Science ®Google Scholar
• Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res.59, 56–58 (1999).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine18, 899–906 (1999).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou WG, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350, 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Flyer DC, Ellingsworth LR et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev. Vaccines6, 809–819 (2007).
   PubMed Web of Science ®Google Scholar
• Godefroy S, Peyre A, Garcia N, Muller S, Sesardic D, Partidos CD. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM197 of diphtheria toxin. Infect. Immun.73, 4803–4809 (2005).
   PubMed Web of Science ®Google Scholar
• Cui Z, Mumper RJ. Topical immunization using nanoengineered genetic vaccines. J. Control. Release81, 173–184 (2002).
   PubMed Web of Science ®Google Scholar
• Shi ZK, Curiel DT, Tang DC. DNA-based non-invasive vaccination onto the skin. Vaccine17, 2136–2141 (1999).
   PubMed Web of Science ®Google Scholar
• Vyas SP, Khatri K, Mishra V. Vesicular carrier constructs for topical immunisation. Exp. Opin. Drug Del.4, 341–348 (2007).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun.75, 2163–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Frerichs DM, Ellingsworth LR, Frech SA et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine26, 2782–2787 (2008).
   PubMed Web of Science ®Google Scholar
• Dean CH, Alarcon JB, Waterston AM et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax-JE) in non-human primates. Hum. Vacc.1, 106–111 (2005).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Med.8, 415–419 (2002).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Sullivan VJ, Dean C et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis.191, 278–288 (2005).
   PubMed Web of Science ®Google Scholar
• Wermeling DP, Banks SL, Huclson DA et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc. Natl Acad. Sci. USA105, 2058–2063 (2008).
   PubMed Web of Science ®Google Scholar
• Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Del. Rev.56, 581–587 (2004).
   PubMed Web of Science ®Google Scholar
• Tezel A, Paliwal S, Shen ZC, Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine23, 3800–3807 (2005).
   PubMed Web of Science ®Google Scholar
• Fang JY, Lee WR, Shen SC, Wang HY, Fang CL, Hu CH. Transdermal delivery of macromolecules by erbium:YAG laser. J. Cont. Rel.100, 75–85 (2004).
   PubMed Web of Science ®Google Scholar
• Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical transdermal delivery: the effect of laser confinement. Lasers Surg. Med.28, 344–347 (2001).
   PubMed Web of Science ®Google Scholar
• Lee WR, Shen SC, Liu CR, Fang CL, Hu CH, Fang JY. Erbium: YAG laser-mediated oligonucleotide and DNA delivery via the skin: an animal study. J. Cont. Rel.115, 344–353 (2006).
   PubMed Web of Science ®Google Scholar
• Jacques SL, McAuliffe DJ, Blank IH, Parrish JA. Controlled removal of human stratum corneum by pulsed laser. J. Invest. Dermatol.88, 88–93 (1987).
   PubMed Web of Science ®Google Scholar
• Frech SA, DuPont HL, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coliagainst travellers’ diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet371, 2019–2025 (2008).
   PubMed Web of Science ®Google Scholar
• Etchart N, Hennino A, Friede M et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine25, 6891–6899 (2007).
   PubMed Web of Science ®Google Scholar
• Baxter J, Mitragotri S. Needle-free liquid jet injections: mechanisms and applications. Exp. Rev. Med. Dev.3, 565–574 (2006).
   PubMed Web of Science ®Google Scholar
• Dean HJ, Chen DX. Epidermal powder immunization against influenza. Vaccine23, 681–686 (2004).
   PubMed Web of Science ®Google Scholar
• Chen DX, Endres R, Maa YF et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine21, 2830–2836 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffman PN, Abuknesha RA, Andrews NJ, Samuel D, Lloyd JS. A model to assess the infection potential of jet injectors used in mass immunisation. Vaccine19, 4020–4027 (2001).
   PubMed Web of Science ®Google Scholar
• Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J. Control. Release117, 227–237 (2007).
   PubMed Web of Science ®Google Scholar
• Widera G, Johnson J, Kim L et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine24, 1653–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharma. Res.24, 1369–1380 (2007).
   Google Scholar
• Miyano T, Tobinaga Y, Kanno T et al. Sugar micro needles as transdermic drug delivery system. Biomed. Microdev.7, 185–188 (2005).
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv. Mater.20, 933–938 (2008).
   PubMed Web of Science ®Google Scholar
• Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine25, 8833–8842 (2007).
   PubMed Web of Science ®Google Scholar
• Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vacc. Immunol.14, 375–381 (2007).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Dekker JP, Harvey NG et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun.74, 6806–6810 (2006).
   PubMed Web of Science ®Google Scholar
• Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine25, 6423–6430 (2007).
   PubMed Web of Science ®Google Scholar